Albany, NY -- (SBWIRE) -- 02/05/2019 -- A report on the global biomarkers and companion diagnostics in oncology market has been added to the vast repository of ResearchMoz.us. It is titled, "Biomarkers and Companion Diagnostics in Oncology". The report banks upon exhaustive primary and secondary research to present in-depth information about the growth drivers, major trends, and restraints in the market. The exhaustive study unravels the opportunities and pitfalls in the market. The report runs through multiple standpoints such as competitive landscape, product, application, and regional segment to understand which ones hold out solid promise.
Several clinical studies clearly point out patients' different responds to the same medicine. For instance, 75% of cancer patient responds negatively to the same anti-cancer drug. Biomarker, a defined molecular characteristic, helps the physician in understanding more about patients' disease state. Biomarkers also helps physician to gain more knowledge about patients' respond to a specific treatment. Many physicians use biomarkers to expedite their clinical decision making. Before prescribing a particular drug for a specific disease, physicians test the patient with a specific biomarker to know if the patient is ready to receive the drug or not. Companion diagnostics (CDx) are mainly in-vitro diagnostics procedure which helps in measuring biomarkers effect in patients' body, before using a particular drug.
Get a Sample PDF with Tables and Figures at: https://www.researchmoz.us/enquiry.php?type=S&repid=2047622
The adoption of companion diagnostics or clinical trials in oncology is rising rapidly due to the various advantages such as improving success rate of diverse clinical trials, and reducing trail size. Different clinical trials in oncology is required because of the aggressive nature of some cancers which are nearly impossible to treat with a specific drug. Increasing collaborations between pharmaceutical companies and diagnostic manufacturers for developing effective solutions in cancer management, and rising investments in research and development activities are factors driving the global biomarkers and companion diagnostics in oncology market.
Different approaches toward research and development investments result in diversified companion diagnostic tests which helps in managing different forms of malignant tumors. Furthermore, breast cancer, non-small cell lung cancer, and colorectal cancer are the most prominent cancer types which exhibits high penetration of CDx. Multi-biomarker assays for treating cancer offers efficiency in the treatment, which in turn fueling the global biomarkers and companion diagnostics in oncology market.
Region wise, Asia Pacific is leading the global biomarkers and companion diagnostics in oncology market as the region has seen rising cases of cancer. Increasing cases of breast cancer, rising mortality rate due to cancer, and growing demand for effective drugs for cancer are also fueling the biomarkers and companion diagnostics in oncology market in the region. The prominent countries in this region are China and Japan. Increasing research and development investments for clinical trials are boosting the biomarkers and companion diagnostics in oncology market in these countries.
Some of the prominent players in the market are Abbott molecular, Avant Diagnostics, BeiGene, Dako, and bioMrieux.
ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.
Albany NY - 12207
Tel: 866-997-4948 (Us-Canada Toll Free)